Clinical trial
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced…
NCT00151034 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00151034 |
|---|---|
| Title | Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer |
| Official title | Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Urologic Neoplasms |
| Intervention type | Drug |
| Interventions | Trastuzumab, Paclitaxel, Carboplatin, Gemcitabine |
| Enrollment | 33 |
| Start date | Sep 1, 2000 |
| Primary completion | Aug 1, 2004 |
| Completion | Oct 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 21, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: